Human disease
Duchenne muscular dystrophy
Mondo defines it as: “Duchenne muscular dystrophy (DMD) is a neuromuscular disease characterized by rapidly progressive muscle weakness and wasting due to degeneration of skeletal, smooth and cardiac muscle.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 1081 | Muscular dystrophy, Duchenne type | Both routes | 4 | Drug |
92.4
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
| Human gene | Score | Evidence |
|---|---|---|
| DMD | 0.87 | 15,916 |
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Ataluren | None of these genes | Approved |
| Casimersen | DMD | Approved |
| Deflazacort | None of these genes | Approved |
| Eteplirsen | DMD | Approved |
| Givinostat | None of these genes | Approved |
| Golodirsen | DMD | Approved |
| Vamorolone | None of these genes | Approved |
| Viltolarsen | DMD | Approved |
| Creatine | None of these genes | Phase 3 |
| Delpacibart Zotadirsen | None of these genes | Phase 3 |
| Deramiocel | None of these genes | Phase 3 |
| Drisapersen | DMD | Phase 3 |
| Edasalonexent | None of these genes | Phase 3 |
| Enalapril | None of these genes | Phase 3 |
| Eplerenone | None of these genes | Phase 3 |
| Fordadistrogene Movaparvovec | None of these genes | Phase 3 |
| Glutamine | None of these genes | Phase 3 |
| Idebenone | None of these genes | Phase 3 |
| L-Citrulline | None of these genes | Phase 3 |
| Metformin | None of these genes | Phase 3 |
| Pamrevlumab | None of these genes | Phase 3 |
| Prednisone | None of these genes | Phase 3 |
| Spironolactone | None of these genes | Phase 3 |
| Tadalafil | None of these genes | Phase 3 |
| Tamoxifen | None of these genes | Phase 3 |
| Ubidecarenone | None of these genes | Phase 3 |
| Epigalocatechin Gallate | None of these genes | Phase 2/3 |
| Suvodirsen | DMD | Phase 2/3 |
| Taldefgrobep Alfa | None of these genes | Phase 2/3 |
| Brogidirsen | None of these genes | Phase 2 |
| Domagrozumab | None of these genes | Phase 2 |
| Ezutromid | None of these genes | Phase 2 |
| Halofuginone | None of these genes | Phase 2 |
| Ifetroban | None of these genes | Phase 2 |
| Oxatomide | None of these genes | Phase 2 |
| Pemirolast | None of these genes | Phase 2 |
| Ramatercept | None of these genes | Phase 2 |
| Satralizumab | None of these genes | Phase 2 |
| Sevasemten | None of these genes | Phase 2 |
| Vepoloxamer | None of these genes | Phase 2 |
| Vesleteplirsen | None of these genes | Phase 2 |
| Canakinumab | None of these genes | Phase 1/2 |
| (+)-Epicatechin | None of these genes | Phase 1/2 |
| (-)-Epicatechin | None of these genes | Phase 1/2 |
| Mecasermin | None of these genes | Phase 1/2 |
| Pentoxifylline | None of these genes | Phase 1/2 |
| Sodium Chloride | None of these genes | Phase 1/2 |
| Tacrolimus Anhydrous | None of these genes | Phase 1/2 |
| Arginine | None of these genes | Phase 1 |
| Bocidelpar | None of these genes | Phase 1 |
| Delandistrogene Moxeparvovec | DMD | Phase 1 |
| Filgrastim | None of these genes | Phase 1 |
| Flavocoxid | None of these genes | Phase 1 |
| Gentamicin | None of these genes | Phase 1 |
| Imlifidase | None of these genes | Phase 1 |
| Prednisolone | None of these genes | Phase 1 |
| Rimeporide | None of these genes | Phase 1 |
| Sildenafil | None of these genes | Phase 1 |
| Rituximab | None of these genes | Unknown |
| Suvodirsen Sodium | DMD | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.